Skip to Content

Ranitidine Injection

Last Updated: April 2, 2020
Status: Discontinued

Products Affected - Description
    • Zantac solution for injection, Teligent, 25 mg/mL, 2 mL vial, 1 count, NDC 52565-0101-10 - discontinued
    • Zantac solution for injection, Teligent, 25 mg/mL, 40 mL vial, 1 count, NDC 52565-0096-01 - discontinued
    • Zantac solution for injection, Teligent, 25 mg/mL, 6 mL vial, 1 count, NDC 52565-0102-01 - discontinued
    • Ranitidine solution for injection, Mylan Institutional, 25 mg/mL, 2 mL vial, 10 count, NDC 67457-0397-99 - discontinued
    • Ranitidine solution for injection, Mylan Institutional, 25 mg/mL, 6 mL vial, 1 count, NDC 67457-0398-62 - discontinued
    • Ranitidine solution for injection, Zydus, 25 mg/mL, 2 mL vial, 10 count, NDC 68382-0422-02 - discontinued
    • Ranitidine solution for injection, Zydus, 25 mg/mL, 40 mL bulk vial, 1 count, NDC 70710-1550-01 - discontinued
    • Ranitidine solution for injection, Zydus, 25 mg/mL, 6 mL vial, 1 count, NDC 68382-0423-06 - discontinued
Reason for the Shortage
    • FDA requested all ranitidine presentations, including injectables, are to be withdrawn from the market. More information can be found at: https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market.
Available Products
    • There are no presentations available

Estimated Resupply Dates

    • All presentations are to be withdrawn from the market.

Updated

Updated April 2, 2020 by Michelle Wheeler, PharmD, Drug Information Specialist. Created May 16, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide